Intrinsiqs

Is Zentalis Pharmaceuticals, Inc. overvalued?

Zentalis Pharmaceuticals, Inc. (ZNTL) — key valuation metrics and fundamentals.

No verdict
Price
$3.56
Fair value
Current P/E
Normal P/E
Market cap
$253.4M
Dividend yield
0.0%
Return on equity
-88.0%
Sector
Healthcare

See the full interactive analysis →

Fair value compares ZNTL's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.